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Novelty and impact:  
Conditionally reprogrammed cells (CRC) methodology could represent a potential model 
for expansion of tumor/non-tumor lung patient cells, promoting the development of lung 
cancer therapeutics. We found that CRC methodology efficiently established non-
malignant lung cell cultures from either tumor and non-tumor samples, while primary or 
metastatic lung tumor cell growth was not promoted under CRC culture conditions. Thus, 
CRC approach cannot be exploited for lung cancer therapeutic testing, as established 
CRC cultures are composed exclusively of (non tumoral) airway basal cells.  
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ABSTRACT 
Availability of tumor and non-tumor patient-derived models would promote the 
development of more effective therapeutics for Non Small Cell Lung Cancer (NSCLC). 
Recently, conditionally reprogrammed cells (CRC) methodology demonstrated exceptional 
potential for the expansion of epithelial cells from patient tissues. However, the possibility 
to expand patient-derived lung cancer cells using CRC protocols is controversial. Here, we 
used CRC approach to expand cells from non-tumoral and tumor biopsies of patients with 
primary or metastatic NSCLC as well as pulmonary metastases of colorectal or breast 
cancers. CRC cultures were obtained from both tumor and non-malignant tissues with 
extraordinary high efficiency. Tumor cells were tracked in vitro through tumorigenicity 
assay, monitoring of tumor-specific genetic alterations and marker expression. Cultures 
were composed of EpCAM+ lung epithelial cells lacking tumorigenic potential. NSCLC 
biopsies-derived cultures rapidly lost patient-specific genetic mutations or tumor antigens. 
Similarly, pulmonary metastases of colon or breast cancer generated CRC cultures of lung 
epithelial cells. All CRC cultures examined displayed epithelial lung stem cell phenotype 
and function. In contrast, brain metastatic lung cancer biopsies failed to generate CRC 
cultures. In conclusion, patient-derived primary and metastatic lung cancer cells were 
negatively selected under CRC conditions, limiting the expansion to non-malignant lung 
epithelial stem cells either from tumor and non-tumor tissue sources. Thus, CRC approach 
cannot be applied for direct therapeutic testing of patient lung tumor cells, as the tumor-
derived CRC cultures are composed of (non tumoral) airway basal cells. 
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INTRODUCTION 
Lung cancer is one of the most common cancers worldwide and the leading cause of 
cancer-related death for both men and women 1.  
Targeted therapies and immune checkpoint inhibitors have significantly improved 
responses in a fraction of patients with non-small cell lung cancer (NSCLC) 2. 
Nevertheless, a majority of patients with lung cancer continue to have very poor outcomes. 
Current therapeutic options are still unsatisfactory due to intrinsic tumor resistance, short 
term antitumor efficacy or drug-toxicity. In fact, even though an encouraging initial benefit 
can occur, it is invariably followed by tumor evolution and progression toward resistant 
disease3-5. The ability to comprehensively characterize the genomic alterations in various 
subtypes of lung cancer at occurrence or at relapse has the potential to 
transform cancer care, by facilitating the identification of novel treatment strategies 6, 7.  
Innovative personalized therapeutic approaches, in the field of deep molecular analysis-
guided targeted therapy and immunotherapy or, more likely, combinations of multi-
disciplinary approaches may represent a promising strategy to improve future lung cancer 
treatment 8. Preclinical models of lung cancer may provide great hints to develop, test and 
validate potentially efficient and durable therapeutic strategies, thus generating advances 
in personalized medicine 9. The establishment of cancer and non-malignant cell in vitro 
models from the same patient would be particularly useful in order to identify and validate 
new genetic anomalies, neo-oncoantigens exploitable for immunotherapy, or to test tumor-
specificity of targeted compounds or therapeutic monoclonal antibodies. Thus, particular 
effort has been recently employed toward the establishment of patient derived xenografts 
(PDX) together with the in vitro expansion of patient material 9. Both approaches need to 
be carefully validated to avoid experimental pitfalls, as demonstrated for the requirement of 
specific mouse background for optimal PDX obtainment, whose patient-like nature needs 
to be always verified 10, 11.  Conditionally reprogrammed cells (CRC) methodology has 
been recently described as an efficient system to expand tumor and non-tumor epithelial 
cells from various tissues in vitro, particularly prostate and breast cancers 12-14. In co-
culture with irradiated mouse fibroblasts as feeder layer and in the presence of the Rho 
kinase (ROCK)-inhibitor Y-27632 adult epithelial cells and cancer cells from epithelial 
tumors have been shown to rapidly generate exponentially growing cultures and might 
represent an excellent model for preclinical testing of anticancer compounds 14, 15. These 
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conditions that induce reprogramming of differentiated epithelial cells associated to active 
cell proliferation have been shown to generate long-term cultures of epithelial "stem like" 
cells 13. Airway epithelial cells have been expanded from multiple districts of healthy or 
pathologic human airway epithelium including lung and trachea, and displayed stem cell 
properties, suggesting the possibility to exploit the CRC procedures also to obtain lung 
cancer cell cultures 16-19. However, controversial results have recently emerged concerning 
the possibility to obtain tumor cell cultures from patient tumor biopsies under CRC 
conditions, including from lung tumors, as some studies reported the obtainment of 
cultures composed by tumor cells or non-tumoral cells from the tumor and healthy tissue, 
respectively, while others reported the selective isolation of non-tumoral cells from either 
sources and others suggested that mixed cultures could be generated 12-14, 20. 
Here, we applied the CRC system to determine whether it may represent a reliable in vitro 
culture model to obtain matched epithelial stem cells from tumor and non-tumoral tissues 
of lung cancer patients. CRC conditions generated long term-cultures of non-malignant 
epithelial cells with high efficiency, from both healthy tissue and tumor biopsies. Similarly 
to primary lung tumors, pulmonary metastasis derived from colon or breast cancers failed 
to generate tumor cell cultures, as lung resident non-tumoral epithelial cells preferentially 
grew under CRC conditions, generating lung epithelial cell cultures. Lung cancer cell 
expansion was not simply overwhelmed by the fast-proliferating non-tumoral cells, as also 
lung cancer brain metastases or patient-derived xenografts (PDX), that are devoid of non-
tumor epithelial cells, failed to generate tumor cell cultures under CRC conditions. In 
contrast, CRC cultures of non-malignant lung cells were obtained with high efficiency and 
displayed lung epithelial stem cell phenotype and properties, compatible with basal cells, 
including the ability to differentiate into various mature respiratory cells. 
Thus, CRC approach, cannot be exploited for the establishment of matched tumor and 
non-tumoral cells from lung cancer biopsies for the development of antitumor therapeutics,  
as this system exclusively allows the long-term expansion of non-malignant lung epithelial 
stem cells.  
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MATERIALS AND METHODS 
In vitro expansion of epithelial cells from tumor and non-tumoral lung tissues. 
Primary lung cancer and metastatic colon and breast tumors as well as healthy lung 
patient tissues were obtained in accordance with consent procedures approved by the 
Internal Review Board of Department of Laboratory Medicine and Pathology, Sant’Andrea 
Hospital, University La Sapienza, Rome. Lung cancer brain metastases were obtained  in 
accordance with consent procedures approved by the Internal Review Board of 
Department of Neurosurgery, Catholic University, Rome, Italy. Tissue dissociation was 
performed as previously described 21, 22. Recovered cells were cultured in conditionally 
reprogrammed cells  (CRC) methodology according to Liu et al 13. Briefly epithelial cells 
were co-cultivated with irradiated murine J2 Swiss 3T3 fibroblasts (Kerafast) in the 
presence of 10µM Rock inhibitor Y-27632 (Selleck), in Fmedium (3:1 v/v  F-12 Nutrient 
Mixture Ham: DMEM) supplemented with 5% FCS, 0.4µg/ml hydrocortisone, 5µg/ml 
insulin, 24µg/ml adenine, 8.4ng/ml cholera toxin, 10ng/ml EGF. Fibroblasts were cultured 
in 10% Characterized HyClone™ Fetal Bovine Serum (U.S.) and irradiated when reached 
70% confluence. All cells were maintained at 37°C in a humidified incubator, with 5% CO2. 
 
Flow cytometry, Immunofluorescence and immunohistochemistry  
Cells and tissues were stained as described in Supplementary Information. 
 
In vitro differentiation of CRC  
To induce differentiation, CRC were deprived of feeder layer and grown in Bronchial 
Epithelial Cell Growth Medium (BEGM, Lonza) for 2 weeks before analysis. 
 
Ali-liquid interface (ALI) cultures  
To induce differentiation, 2x105 CRC were cultured for 1 week in PneumaCult–Ex 
Medium (Stem Cell Technologies), until confluence was reached. Then, 1,5x105 
cells were plated in Corning 3460 inserts, and cultured in PneumaCult –Ex Medium 
in both basal and apical chambers for 4 days, afterwards medium was replaced with 
PneumaCult –ALI Medium in the basal chamber, leaving the apical chamber empty 
for  28days.  
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Proliferation assays of CRC  
To determine cell growth rate of CRC cultures 100000 cells were plated on feeder layer in  
complete growth medium and counted by trypan blue exclusion every 6 days. Proliferation 
index was calculated as population doublings (PD) using the following formula: 
PD=3.32(log cell number counted /cell number plated at day0). 
 
Generation of subcutaneous xenografts in NSG  (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice 
Five hundred thousand cells were mixed 1:1 with matrigel and injected in the flank of NSG 
mice. Three injections were performed for each sample of cultured cells, while a single 
injection was performed for freshly dissociated tumor samples. 
 
DNA extraction and mutational analysis 
DNA was extracted from patient tissue or from 100000 cultured cells with DNA Easy Blood 
and Tissue kit (Qiagen) and subjected to next generation sequencing using Ion 
AmpliSeq™ Colon and Lung Cancer Research Panel v2 (Life Technologies).  
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RESULTS 
Conditionally reprogrammed cells (CRC) cultures generated from healthy and tumor 
lung tissue are composed of lung epithelial cells lacking tumorigenic potential  
The aim of this study was to determine whether the CRC methodology may represent a 
reliable in vitro culture model to obtain matched tumoral and non malignant epithelial cell 
cultures, respectively from tumor and non-tumoral lung patient tissues. Paired primary lung 
tumor and healthy lung tissue specimens were obtained from 19 non small cell lung cancer 
(NSCLC) patients that underwent therapeutic surgical resection (Table 1). In the attempt to 
establish tumor and non-tumoral cultures in vitro, freshly dissociated cells from squamous 
cell carcinoma (SCC), adenocarcinoma (AC) large cell neuroendocrine carcinoma 
(LCNEC), carcinoid tumors (CT) and from their corresponding non-malignant tissues, 
collected distant from the tumor, were seeded in CRC conditions, medium was replaced 
twice a week until the cells reached confluence (approximately 2 weeks, passage1) and 
then passaged twice a week with new feeder layer as previously described 13. Initial 
phases of tumor sample-derived cultures generated highly heterogeneous cell populations 
followed by more homogeneous cell populations in the next weeks. A morphologically 
homogeneous culture was completely reached already at passage 2 (3-4 weeks) (Figure 
1A). Evaluation of marker expression was performed at passage 2 and showed that 
cultured cells displayed epithelial phenotype (approximately 90% of EpCAM+ cells) and 
were almost free of human fibroblast contamination (<2% of CD90+ cells), since growth of 
these cells was not favored under CRC conditions (Figure 1B top panels). Feeder cells 
represented a minuscule fraction (<3% murine MHC+ cells), thus not affecting subsequent 
analyses (Figure 1B bottom panels). CRC displayed prominent and prolonged growth 
ability as shown for the 30 population doublings measured in approximately 30 days of cell 
proliferation monitoring, proving that CRC system may represent optimal growth conditions 
for prolonged expansion of epithelial cells from patient samples (Figure1C). Some cultures 
were monitored for at least 4 months and their growth rate did not decrease over time. 
Moreover, non malignant tissue- and tumor-derived cells displayed a highly comparable 
growth rate. These results suggested an apparent morphological, phenotypical and 
functional similarity among the tumor and non tumor-derived CRC cultures.  
Given that non-tumoral and tumor tissues were obtained from different portions of the 
same surgical specimen, the possibility that rare tumor cells were disseminated within non-
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tumoral surrounding tissue, could not be excluded. If present they could potentially 
overgrow in culture due to proliferative advantage expected for their malignant phenotype. 
On the other hand, previous reports showed that proliferation of non-malignant epithelial 
cells is promoted under these culture conditions 20. In order to determine the malignant or 
non-malignant nature of CRC cultures, their tumorigenic potential was evaluated following 
subcutaneous injection in NSG mice. In view of the fact that the efficiency of PDX 
obtainment from fresh samples was approximately 40%, tumorigenicity assay was 
evaluated only with CRC corresponding to patient samples that had shown the ability to 
generate PDX when injected under the same conditions. In contrast to 5x105 fresh tumor 
cells, that generated patient-like tumors within 1-2 months post-injection, cultured CRC (up 
to 1x106 cells) either originating from tumor and non-tumor tissue, were never able to 
generate a tumor in vivo (up to 5 months monitoring), suggesting that CRC cultures were 
composed of non-tumorigenic lung epithelial cells (Figure 1D). These results implied that 
tumorigenic cells originally present within the patient tumor sample were unable to 
proliferate and establish a culture under CRC conditions. 
CRC-cultures generated from different types of lung cancers rapidly lose patient-
specific genetic mutations or tumor specific antigens due to selective growth of 
healthy pulmonary cells 
To clarify whether the tumor tissue-derived cultures were composed of tumor cells that had 
lost their tumorigenicity upon in vitro expansion or derived from the selective proliferation 
of non-malignant epithelial cells dispersed within the tumor tissue, we identified genetic 
marks of tumor cells, allowing to discriminate among paired tumor and non-tumoral cells 
and to track tumor cells within CRC cultures. Ion torrent next generation sequencing (Ion 
AmpliSeq™ Colon and Lung Cancer Research Panel V2 , Life Technologies) of tumor and 
non-tumor patient tissues and their corresponding CRC at passage-2 and -4 showed that 
most patient tumor samples contained 2 of the 22 hotspot gene mutations, representing a 
suitable genetic signature exploitable to track cancer cells in culture at early and late 
passages (Table 2). No mutations were detected in the corresponding non tumoral tissue 
(except for a MET mutation present in both tumor and non-tumor patient tissue, in line with 
a germline heterozygous mutation) thus validating the nature of patient samples (Table2). 
Tumor-derived passage-2 CRC displayed barely detectable/lack of genetic mutations, that 
completely disappeared at passage 4 in all samples, thus confirming the hypothesis that 
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tumor cells were negatively selected and rapidly lost during CRC culture, in favor of an 
efficient expansion of non-malignant (mutation negative) cells (Table 2).  
Time course analysis of DNA samples confirmed the rapid reduction of the mutation-
positive tumor cell fraction within cultures, in agreement with their counter-selection due to 
concomitant overgrowth of non-tumoral cells. Mutation-bearing cells were undetectable in 
passage 4-CRC cultures expanded from originally-mutated patient tumor samples, proving 
that the initially highly heterogeneous cell culture rapidly originated a virtually pure 
population of non-malignant cells.  
In addition to patient-specific genetic lesions, CRC cultures generated from 
neuroendocrine lung tumors lacked the diagnostic marker CD56, found in the tumor of 
origin, further confirming that CRC system, did not allow the growth of tumor cells (Figure 
2A). Similar results were found for another neuroendocrine lung tumor, a CD56+ carcinoid 
that generated CD56-negative CRC cultures. Time course cytofluorimetric analysis 
showed a rapid decrease of CD56+ cells (5.8% at passage 1 and 0.2% at passage 2) 
(Figure 2B) in line with a tumor cell-depleting culture. Tumor cells survived for several 
weeks as adherent clones, that appeared less vital after few weeks and were gradually 
lost due to the growth of surrounding non-tumoral epithelial lung cells (Supplementary 
Figure 1A).  
CRC cultures derived from pulmonary metastases of colon or breast cancers are 
composed by lung epithelial cells 
Finally, CRC obtained from three samples of pulmonary metastases of CK20+ colorectal 
cancers (Table 1) lacked the colon cancer-specific marker CK20 while expressed lung 
tissue antigen CK7, as expected for cells of lung origin and not for colon derived-cells 
(Figure 2C right panels), as the two antigens may contribute to differential diagnosis of 
tumors of colon or lung origin 23-25 and in line with immunohistochemistry analysis of the 
corresponding patient tissues where, clearly, colorectal cancer metastasis is CK20+/CK7-, 
while the surrounding patient lung tissue is CK20-/CK7+ (Figure 2C left panels). 
Supplementary Figure 1B shows the expected positivity of control colon cancer cells for 
CK20 and lung cancer cells for CK7 antibody 21, 22, 26. Time course flow cytometric analysis 
of CK20 and CK7 expression revealed a rapid and progressive reduction of CK20+ cells at 
passage 2, that completely disappeared at passage 4 and a concomitant massive increase 
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of CK7+ cells, constituting the predominant cell population at passage 2 and more than 
90% of cells at passage 4 (Supplementary Figure 2C). These results showed that 
pulmonary metastases of colorectal cancers, generated CRC-cultures composed of 
pulmonary epithelial cells, presumably derived from the proliferation of lung cells resident 
in the metastasized respiratory tissue. Expression of CK5 and CK14 confirmed that these 
CRC cultures were composed of cells compatible with airway basal cells 16 
(Supplementary Figure 1D). In line with these results, we found that mutation-positive 
colon cancer cells were progressively lost with culture as shown by low (p4) and 
undetectable (p8) fraction of the p53/NRAS/ErbB4 mutations-bearing cells observed 
through next generation sequencing (Table 2B). These results enforce the assumption that 
tumor cells are lost under CRC culture conditions, excluding the possibility that CRC 
cultures may be composed of tumor cells lacking the genetic mutations and endowed with 
a possible growth advantage over mutation-positive tumor cells. Similarly, CRC obtained 
from pulmonary metastasis of c-erbB2+++ breast cancer lacked the specific diagnostic 
marker (Figure 2D). 
The final evidence that CRC methodology is suitable for the growth of non-malignant 
epithelial respiratory cells was that epithelial CRC cultures could be obtained from healthy 
lung tissue derived from non oncologic patients (Figure 2E).  
Lung cancer cell cultures cannot be established from metastatic lung cancers or 
from patient-derived xenografts, under CRC conditions   
In order to test whether the lack of tumor cells in passaged CRC cultures was due to the 
predominant growth of non-tumoral epithelial cells or to inability of lung tumor cells to 
survive and proliferate under CRC conditions, we evaluated the possibility to generate 
CRC cultures from lung tumor samples devoid of non-tumoral pulmonary epithelial cells, 
i.e. from lung cancer metastasis in non-epithelial tissues (brain) and from lung cancer 
patient derived xenografts (PDX) as non-tumoral human epithelial cells are lost following in 
vivo tumor passage. Two lung cancer brain metastases and five PDX (3 AC and 2 SCC  
subtype) samples were analyzed in these experiments. Metastatic lung tumor cells formed 
adherent clones and survived for several weeks under CRC conditions, however they did 
not actively grow and appeared gradually less healthy, in contrast to a fraction of the same 
cells cultured under standard conditions for cancer stem cells (CSC), demonstrating high 
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viability and proliferative capacity of the tumor cells, when cultured under appropriate 
conditions 21, 22. The fraction of CEA+ tumor cells, highly abundant in the patient tumor 
(Figure 3A top panels) as well as in the CSC cultures, gradually decreased with CRC 
culture passages (in the first weeks) and after 5 weeks CRC cultures completely lacked 
CEA-positive tumor cells and the exon 19 EGFR deletion originally detected in the patient 
tumor (as shown in Supplementary Figure 2 murine feeder layer cells represented the only 
cell population detectable), and retained under CSC culture conditions (Figure 3A lower 
panels and Supplementary Information). Similarly, the human epithelial antigen EpCAM, 
marking freshly dissociated PDX cells, was gradually lost in culture, and after prolonged 
time (5 weeks) the cell population resulted composed exclusively of murine cells (human 
HLA negative) (Figure 3B). Thus, CRC methodology did not allow the expansion of lung 
tumor cells even in the absence of the growth-competitors fast-proliferating lung epithelial 
cells, demonstrating that CRC methodology does not represent a suitable model for 
supplying tumor cells from lung cancer patients suitable for research and therapeutic 
purposes.  
CRC cultures are composed of lung epithelial stem-like cells with multiple 
differentiation potential  
Other studies have shown that conditionally reprogrammed cells obtained from epithelial 
tissues represent a stem-like state of adult epithelial cells 27. To determine if lung  tissue-
derived CRC cultures were composed of stem-like cells we compared them with the same 
cells cultured under standard conditions for pulmonary cells (BEGM). CRC displayed 
nuclear retention of β-catenin, higher expression of antigens associated with adult 
epithelial stem cells such as Integrin α6, Integrin β1 and NGFR, confirming a stem-like 
phenotype of CRC cultures, in agreement with previous results (Figure 4A-B) 17, 27.  
Prolonged culture of CRC under Air-Liquid Interface culture conditions, allowed their 
differentiation into mature respiratory cells, as shown by the expression of lineage specific 
markers for ciliated cells (acetylated α-tubulin) and goblet cells (mucin 5B) after 4 weeks of 
differentiation (Figure 4C). In the orthogonal projection image acetylated tubulin and mucin 
5B antigens are visible at the apical surface of the monolayer-forming cells as compared 
with basal nuclei staining, compatible with the expected cilia and mucin 5B localization.
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DISCUSSION 
Although targeted therapy has improved lung cancer patient clinical management and 
course, wide effort is still required for the long term outcome improvement, as most tumors 
initially responding to targeted agents, invariably develop resistance mechanisms6. New 
targets need to be identified both in treatment-naive patients as well as to escape 
treatment-induced tumor progression and resistance. The possibility to expand patient 
tumor material in vitro associated with paired non-malignant samples of the same patient 
would represent an outstanding tool to identify tumor specific drug-targetable mutations or 
new tumor antigens for immunotherapy and to identify treatment escape mechanisms that 
concur to tumor resistance, in order to exploit them as new targets to circumvent drug-
resistance. Recent studies reported the possibility to establish in vitro culture of tumor and 
non-tumor patient-derived cells with high efficiency 12, 13. In co-culture with irradiated 
mouse fibroblasts as feeder layer and in the presence of the Rho kinase (ROCK)-inhibitor 
Y-27632 adult epithelial cells and cancer cells from epithelial tumors have been shown to 
generate exponentially growing cultures 14, 15. CRC cultures of airway epithelial cells have 
been obtained from multiple districts of the human airway epithelium including lung and 
trachea, and displayed stem cell properties 16, 17. However, controversial results have 
recently been reported concerning the possibility to obtain tumoral and non-tumoral cell 
cultures from lung cancer patient biopsies under CRC protocols 12, 14, 20. In fact, while some 
studies have reported the possibility to expand both non tumor and tumoral cells under 
CRC protocols, others have clearly demonstrated that only non-malignant cell cultures can 
be obtained both from healthy lung tissue as well as from lung cancer specimens 20. Thus, 
the possibility that only non-malignant cells contained within patient tumor biopsies are 
able to proliferate under CRC conditions has been reported and very recently the 
possibility that mixed cultures can grow under these conditions for some tumor types has 
been taken into consideration 12, 20. Here, we applied the CRC methodology with the aim to 
deeply investigate and determine whether it may represent a reliable in vitro culture model 
to obtain matched epithelial stem cells from non-tumoral and tumor tissue from lung 
cancer patients. 
The CRC methodology proved to be exceptionally efficient in the establishment of cell 
cultures, in fact approximately 100% patient samples yielded exponentially growing long 
term cultures of epithelial cells (EpCAM positive) (Figure 1). However, our results clearly 
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demonstrated that cell cultures established from primary lung tumors were not composed 
of tumor cells but, they were virtually pure populations of non-malignant cells originated by 
the preferential overgrowth of non-malignant epithelial cells, originally contained within the 
tumor. Rapid growth of pulmonary epithelial cells present within tumors determined tumor 
cell fraction decrease and eventually loss after few passages in culture, non only in the 
case of lung cancers, but even in pulmonary metastases of colon or breast cancers, 
suggesting that CRC approach is highly suitable for the growth of respiratory cells that 
predominate over tumor cell types of various origin and aggressiveness. Finally, we 
analyzed whether in the absence of lung epithelial "competitor" cells, the establishment of 
a tumor cell culture could be obtained, although at lower proliferation rates. However, even 
in the epithelial cell-free lung cancer brain metastases or in the case of lung cancer PDX 
(that after in vivo passage are devoid of non-tumor cells), malignant cells survived but did 
not proliferate to form CRC cultures, and after several weeks, only murine cells (murine 
MHC+/human HLA-) cells were detectable in cultures. In contrast, a fraction of tumor cells 
obtained from the same sample was able to grow under conditions suitable for malignant 
cells, proving their viability and capacity to proliferate when appropriate methodologies are 
applied.  
The presence of lung cancer-associated genetic defects was exploited to track tumor cells 
in vitro. Multiple mutations were considered in order to exclude the possibility that a single 
mutation present in a small fraction of tumor cells could be lost due to the possible growth 
advantages of other mutation-negative tumor cell fractions. Moreover, the detection of 
tumor-restricted markers expressed on the majority of tumor cells and not on non-
malignant lung cells were used as additional tracking system, as in the case of CD56+ 
neuroendocrine lung tumors, or pulmonary metastases of CK20+ colon cancers and 
HER2-overexpressing breast cancers. Similarly, metastatic lung cancer could be easily 
tracked within the epithelial cell marker-negative brain microenvironment or, in the case of 
lung cancer PDX, human antigens-positive cancer cells could be distinguished from 
murine cells. 
In agreement with other reports showing that CRC represent a stem-like state  of adult 
epithelial cells we found that the expression of antigens related to the stemness of lung 
epithelial cells, as Integrin α6, Integrin β1 and NGFR was increased in these cultures 
compared to the same cells grown under standard conditions (Figure 4). Finally, Air-Liquid 
Interface culture methodology revealed the multiple differentiation potential of CRC 
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cultures, in fact CRC cultivated for a prolonged time under these conditions expressed 
markers of mature ciliated and goblet cells, in agreement with previous reports (Figure 4) 
20.  
In conclusion, our results showed that CRC system cannot be exploited to expand primary 
or metastatic lung tumor cells for the direct improvement/testing of anti-cancer strategies 
with great relevance for preclinical oncologic experimentation. However, it remains 
possible that tumor cells of different origin might be manageable to culture under these 
conditions (preferentially if not localized in the lung tissue). On the other hand, we found 
that, this methodology can provide a powerful unprecedented in vitro model of lung stem 
cell expansion, possibly providing new hints to understand cellular transformation, The 
exceptional success in culture establishment of stem cell with multiple differential potential 
from patient material would greatly imply CRC methodology applications for personalized 
therapy of various non oncologic pulmonary pathologies, possibly constituting suitable in 
vitro models or models for cellular therapy for cystic fibrosis, idiopathic pulmonary fibrosis 
or other severe lung diseases 19, 28. 
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FIGURE LEGENDS 
Figure 1. Phenotype and functional analysis of conditionally reprogrammed cells (CRC) 
obtained from tumor and non-tumoral lung tissue. A) Images showing the morphology of 
CRC cultures obtained from tumor (T) and non tumoral (N) tissues at passage 2 (3 weeks 
culture). B) Flow cytometric analysis of CRC for the expression of epithelial (EpCAM), 
human fibroblasts (CD90) or murine stroma (mMHC) markers, as indicated. The flow 
cytometry analysis is representative of 15 samples analyzed. C) Population doublings of 
CRC obtained from one matched tumor (T) / non tumoral (N) tissue sample monitored 
from passage 2 for 30 days. Standard error bars are relative to three wells replicates 
counted at each time point. Paired growth curves are representative of 3 patient-derived 
matched samples. D) Tumorigenic ability of freshly-obtained patient tumor cells (T1) or 
CRC expanded from tumor (T1-CRC) or non-tumoral (N1-CRC) tissue derived cells. 
Tumor growth was monitored over 13 weeks, as indicated. The assay is representative of 
5 paired CRC samples analyzed. 
Figure 2 CRC-cultures rapidly lose tumor-specific antigens within few passages due to 
selective growth of healthy pulmonary cells. A) Hematoxilyn and Eosin (HE) or CD56 
immunoistochemistry of a CD56+ Large Cell Neuroendocrine Carcinoma (T6-pt) and CD56 
flow cytometric analysis of CRC obtained from tumoral (T6-CRC) and non-tumoral (N6-
CRC) tissue of the same patient. Glioblastoma stem cells were used as positive control for 
CD56 expression.  B) Diagnostic CD56 immunoistochemical analysis of a Carcinoid Tumor 
(T32-pt) and CD56 flow cytometric analysis of the corresponding CRC (T32-CRC) 
obtained at passage 1(p1) or 2 (p2). C)  Hematoxilyn and Eosin (HE), or diagnostic CK20 
and CK7 immunoistochemistry of pulmonary Colon Cancer metastasis (T4-pt) and CK20 
and CK7 flow cytometric analysis of CRC obtained from tumoral (T4-CRC) and non-
tumoral (N4-CRC) tissues of the same sample. D) c-ErbB2 immunoistochemistry of 
pulmonary breast cancer metastasis (T28-pt) and immunocitochemistry of tumoral (T28-
CRC) and non-tumoral (N28-CRC) CRC-derived Cell Blocks obtained from the same 
patient. E) Pan-CK and CK7 flow cytometric analyses of CRC obtained from non oncologic 
patient tissues (representative of 3 samples). 
Figure 3. Tumor cell cultures cannot be established from metastatic lung cancers and from 
PDX under CRC methodology. A) (left) Diagnostic Hematoxylin and Eosin staining (HE) 
Page 19 of 40
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
19 
 
and immunoistochemistry for CEA of Lung Cancer brain Metastasis (T31). (Middle) CEA 
flow cytometry of patient tumor cells cultured in CSC or CRC conditions as indicated. 
(Right) Detection of EGFR Ex19 deletion in patient tumor cells cultured in CSC or CRC 
conditions. Comparison of database EGFR sequence with sequence of PCR-amplified 
EGFR cDNA of CSC or CRC. B) Flow cytometric time course (week 0 to 5) analysis of 
EpCAM expression in CRC cultures obtained  from T7 patient-derived xenograft cells. HLA 
flow cytometric expression on the same cells performed after 5 weeks culture. 
Figure 4. CRC display stem cell phenotype. A) β-Catenin immunofluorescence of CRC and 
the same cells (BEGM) cultured in standard conditions for primary bronchial epithelial 
cells. Nuclei in immunofluorescence images are fluorescently blue-labeled with DAPI and 
β-catenin with green Alexa Fuo 488. B) Flow cytometry for integrin-α6, -β1 and NGFR 
expression on CRC (red) and BEGM cells (light gray). Negative control antibody staining is 
indicated in black. C) Confocal microscopy of CRC differentiated in Air-liquid interface 
culture for 28 days, fixed and fluorescently labeled with DAPI (nuclei), or antibodies for α-
tubulin-Alexa Fluor 488 (ciliated cells) or MUC5B-Alexa Fluor 647 (goblet cells). The upper 
stripe (XZ) represents an orthogonal projection image where nuclei are visible at the 
bottom and stained antigens at the apical surface of the monolayer-forming cells. 
Table 1. Clinical staging, classification and diagnostic markers of primary lung tumors, 
pulmonary metastases of colon and breast tumors and lung cancer brain metastases. 
Table 2. CRC-cultures rapidly lose patient-specific genetic mutations within few passages 
in culture due to selective growth of healthy pulmonary cells. Next generation sequencing 
of 22 lung and colon cancer associated genes (Ion AmpliSeq™ Colon and Lung Cancer 
Research Panel v2) performed on DNA isolated from tumor (T) and healthy (N) lung (A) or 
colon (B)  patient tissues (pt) and from corresponding CRC at passage (p) 1, 2, 4 or 8, as 
indicated. 
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 Primary tumors of the lung 
Sample Patient (sex/age) Tumor subtype TNMstage/grading Diagnostic markers expression 
#1 M/67 AC pT3 pN2-IIIA/G3 TTF1+, NapsinA+, p63-, ALK-, ROS1- 
#2 M/69 SCC pT1a pN0-IA/G2 p63+, CK7- ,TTF1- 
#5 M/59 AC pT2a pN2-III A/G3 ALK-, ROS1- 
#6 M/71 LCNEC 
 
pan-CK (AE1-AE3)+, CD56+, TTF-1-, CromograninA-, Synaptofisin-, p63- 
#7 M/76 AC pT2a pN2-III A/G1 TTF1+, ALK-, ROS1- 
#8 F/60 AC pT3 pN2-III A TTF1+ 
#16 M/73 AC pT2a pN0-IB/G3 TTF1+, ALK-, ROS1- 
#18 M/66 SCC pT3 pN0-IIB/G3 p63+, CK7- ,TTF1- 
#19 M/55 AC pT2a pN2-IIIA/G3 TTF1+, ALK-, ROS1- 
#20 F/67 SCC pT1b pN1-IIA/G2 p63+, CK7- ,TTF1- 
#21 M/48 AC pT1b pN0-IA/G1 TTF1+, NapsinA+, ALK-, ROS1- 
#22 F/65 AC pT2a pN2-IIIA/G2 TTF1+, ALK-, ROS1- 
#23 M/63 AC pT2a pN2-IIIA/G3 TTF1+, ALK-, ROS1- 
#25 F/75 AC IV TTF1+, ALK-, ROS1- 
#29 F/69 AC pT2a pN0-IB CK7+, TTF-1+, NapsinA+, p63+ CK5/6- 
#30 F/73 AC pT1b pNo-IA TTF1+, NapsinA+ 
#32 M/76 Carcinoid pT1a pN0-IA CD56+, Synaptofisin+ 
#33 M/73 SCC pT2a pN0-IB p63+, CK7- ,TTF1- 
#35 M/71 SCC pT3 pN0-IIB p63+, CK7- ,TTF1- 
Pulmonary metastases 
Sample Patient (sex/age) Tumor type stage Diagnostic markers expression 
#4 M/65 Colon cancer IV CK20+, CDX2+, TTF-1-, CK7-, NapsinA- 
#26 M/76 Colon cancer IV CK20+, CDX2+, TTF-1-, CK7-, NapsinA- 
#27 M/83 Colon cancer IV CK20+, CDX2+, TTF-1-, CK7-, NapsinA- 
#28 F/51 Breast cancer IV CK7+, c-ErbB2+++, ER-, PGR- 
Lung Cancer Brain Metastases 
Sample Patient (sex/age) Tumor type stage Diagnostic markers expression 
#m34 M/63 SCC IV EGFR WT, ALK- 
#m31 F/49 AC IV EGFR -exon 19 mutation (c.2235_2249del15) 
 
Table 1 
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sample mutated gene (site of mutation): % of mutation   
T1-pt p53(p.Val173Leu/Met): 19% KRAS(p.Gly12Cys/Arg/Ser): 30%   
N1-pt wt wt   
T1-CRCp2 wt wt   
N1-CRCp2 wt wt   
T6-pt p53(p.Ala159Ser/Pro/Thr): 48%  MET (p.Arg359Gln): 72%   
N6-pt wt MET (p.Arg359Gln): 52%   
T6-CRCp2 p53(p.Ala159Ser/Pro/Thr): 4,8% MET (p.Arg359Gln): 54%   
N6-CRCp2 wt MET (p.Arg359Gln): 52%   
T19-pt KRAS(p.Gly13Cys): 21,2% PTEN (p.Asn334fs): 15%   
N19-pt wt wt   
T19-CRCp4 wt wt   
N19-CRCp4 wt wt   
T20-pt p53(p.Glu285Val): 34,6% PI3KA (p.Glu542Lys): 29,8%   
N20-pt wt wt   
T20-CRCp4 wt wt   
N20-CRCp4 wt wt   
T2-pt p53(p.Lys132Met/Arg/Thr): 41%     
N2-pt wt     
T2-CRCp2 wt     
N2-CRCp2 wt     
T16-pt p53(p.Arg248Gln): 30%     
N16-pt wt     
T16-CRCp1 p53(p.Arg248Gln): 4,4%     
T16-CRCp2 wt     
T16-CRCp4 wt     
N16-CRCp4 wt     
T18-pt p53(p.Arg273Leu): 48%     
N18-pt wt     
T18-CRCp1 wt     
T18-CRCp2 wt     
T18-CRCp4 wt     
N18-CRCp4 wt     
B 
sample mutated gene (site of mutation): % of mutation 
T4-pt p53(p.Arg175Leu/Pro/His): 14% NRAS(p.Gln61Glu|/Lys): 7.4%   ErbB4 (p.Ala287Glu): 6.7% 
N4-pt wt wt wt 
T4-CRC p4 p53(p.Arg175Leu/Pro/His): 6,8% NRAS(p.Gln61Glu/Lys): 4.5% ErbB4 (p.Ala287Glu): 4% 
T4-CRC p8 wt wt wt 
N4-CRC p4 wt wt wt 
 
                                                         Table 2 
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